Skip to main content
BRVE
NASDAQ Life Sciences

Braveheart Posts Q3 Loss of $26.5M; $503.5M Cash Funds Runway Into 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$19.62
Mkt Cap
$1.767B
52W Low
$16.7
52W High
$32
52W Position info
17% above low
Off High info
39% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

BRVE sits 17% above its 52-week low of $16.7.

Summary

Braveheart reported a $26.5 million Q3 2026 net loss and $503.5 million in cash, enough to fund operations into 2029. The company said its nHCM Phase 3 and fixed-dose oHCM Phase 2b trials should start in the first half of 2027.


Key Events · Earnings and Guidance · BRVE

  • Q3 Loss Narrows to $26.5M

    Net loss was $26.5 million, or $0.51 per share, versus $59.1 million a year earlier — a comparison inflated by a $58.8 million in-process R&D charge in the prior-year quarter.

  • Cash of $503.5M Funds Runway Into 2029

    Cash, cash equivalents and investments stood at $503.5 million at September 30, 2026, up from $89.2 million at year-end 2025 following the August IPO.

  • Spending Ramps With Phase 3 Enrollment

    R&D expense was $17.5 million and G&A $12.6 million for the quarter. G&A included $7.8 million of non-cash stock-based compensation, of which $6.1 million related to liability-classified awards remeasured each period.

  • Two Trials Slated for First Half 2027

    The FDA end-of-Phase 2 meeting for NOBLEHEART-HCM is complete, and both NOBLEHEART-HCM (nHCM Phase 3) and TRUEHEART-HCM (fixed-dose oHCM Phase 2b) are planned to initiate in the first half of 2027.


Analysis · BRVE · Life Sciences

The quarter's headline is the balance sheet: $503.5 million in cash and investments after the August IPO funds operations into 2029, so there is no near-term financing need and no dilution overhang from this filing. Spending is ramping as expected. R&D rose to $17.5 million from essentially nothing a year ago as LIONHEART-HCM enrolls, and G&A hit $12.6 million, including $7.8 million of non-cash stock compensation. The net loss narrowed to $26.5 million from $59.1 million, but that comparison is flattered by a $58.8 million in-process R&D charge in the year-ago period, not by improving economics. On the pipeline, the FDA end-of-Phase 2 meeting for NOBLEHEART-HCM is done, and both NOBLEHEART and the fixed-dose TRUEHEART-HCM Phase 2b are slated to start in the first half of 2027. The LIONHEART interim LVOT analysis is expected in the second half of 2027 — a long gap before the next major readout.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BRVE was trading at $19.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $16.70 to $32.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BRVE - Latest Insights

BRVE
Nov 10, 2026, 4:03 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.62
Real-time Price: $20.50 info
Change: +$0.880 (+4%) info
Market Cap: $1.842B info
BRVE
Nov 06, 2026, 3:17 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.30
Real-time Price: $20.50 info
Change: +$2.20 (+12%) info
Market Cap: $1.842B info
BRVE
Nov 06, 2026, 3:15 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $18.30
Real-time Price: $20.50 info
Change: +$2.20 (+12%) info
Market Cap: $1.842B info
BRVE
Sep 08, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $29.41
Real-time Price: $20.50 info
Change: -$8.91 (-30%) info
Market Cap: $1.842B info
BRVE
Aug 14, 2026, 4:55 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $27.03
Real-time Price: $20.50 info
Change: -$6.53 (-24%) info
Market Cap: $1.842B info